Use of recombinant factor VIIa in a thrombocytopenic patient with spontaneous intracerebral haemorrhage

Stefano Busani; Marco Marietta; Alberto Pasetto; Massimo Girardis

doi:10.1055/s-0037-1616257

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2005; 93(02): 381-382
DOI: 10.1055/s-0037-1616257

Case Report

Schattauer GmbH

Use of recombinant factor VIIa in a thrombocytopenic patient with spontaneous intracerebral haemorrhage

Stefano Busani

¹Cattedra e Servizio di Anestesiologia e Rianimazione, Università di Modena ee Reggio Emilia e Policlinico di Modena

,

Marco Marietta

²Cattedra e Divisione di Ematologia, Università di Modena ee Reggio Emilia e Policlinico di Modena

,

Alberto Pasetto

¹Cattedra e Servizio di Anestesiologia e Rianimazione, Università di Modena ee Reggio Emilia e Policlinico di Modena

,

Massimo Girardis

¹Cattedra e Servizio di Anestesiologia e Rianimazione, Università di Modena ee Reggio Emilia e Policlinico di Modena

› Author Affiliations

Abstract

Full Text

References

References
1 Dennis MS, Burn JP, Sandercock PA. et al Longterm survival after first-ever stroke: the Oxfordshire Community Stroke Project.. Stroke 1993; 24: 796-800.
2 Qureshi I A, Thurim S, Broderick JP. et al Spontaneous intracerebral hemorrhage.. N Engl J Med 2001; 344: 1450-60.
3 Broderick J, Adams HP, Barsan W. et al Intracerebral haemorrhage more than twice as common as subarachnoid haemorrhage.. J Neurosurg 1993; 78: 188-91.
4 Brott T, Broderick J, Kothari R. et al Early hemorrhage growth in patients with intracerebral hemorrhage.. Stroke 1997; 28: 1-5.
5 Kazui S, Naritomi H, Yamamoto H. et al Enlargement of spontaneous intracerebral haemorrhage: incidence and time course.. Stroke 1997; 28: 2370-5.
6 Mayer SA. Ultra-early hemostatic therapy for intracerebral hemorrhage.. Stroke 2003; 34: 224-9.
7 Hedner U. NovoSeven® as a universal haemostatic agent.. Blood Coagul Fibrinolysis 2000; 11: 107-11.
8 Abshire T, Kenet G. Recombinant factor VIIa : review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors.. J Thromb Haemost 2004; 2: 899-909.
9 Hunault M, Bauer KA. Recombinant factor VIIa for the treatment of congenital factor VII deficiency.. Semin Thromb Hemost 2000; 26 (04) 401-5.
10 Friederich PW, Wever PC, Briet E. et al Successful treatment with recombinant factor VIIa of therapy- 'resistant severe bleeding in a patient with acquired von Willebrand disease.. Am J Hematol 2001; 66: 292-94.
11 Jeffers L, Chalasani N, Balart L. et al. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 2002; Jul 123 (01) 118-26.
12 Grounds M. Recombinant factor VIIa and its use in severe bleeding in surgery and trauma: a review.. Blood Reviews 2003; 17: S11-S21.
13 Monroe DM, Hoffman M, Oliver JA. et al Platelet activity of high-dose factor VIIa is independent of tissue factor.. Br J Haematol. 1997; 99: 542-7.
14 Poon MC, Demers C, Jobin F. et al Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia.. Blood 1999; 94: 3951-3.
15 Vidarsson B, Onudarson PT. Recombinant factor VIIa for bleeding in refractory thrombocytopenia.. Thromb Haemost 2000; 83: 634-5.
16 Gerotziafas GT, Zervas C, Gavrielidis G. et al Effective haemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening haemorrhage.. Am J Hematol 2002; 69: 219-22.
17 Goodnough LT. Experiences with recombinant human factor VIIa in patients with thrombocytopenia. Semin Hematol 2004; 41 S (01) 25-9.
18 Mayer SA, Brun N, Broderick J. et al Recombinant factor VIIa for acute intracerebral haemorrhage. 5 th World Stroke Congress. June 23–26,2004. Vancouver B.C; Canada: Abstracts Book p.48